| ko05166 |
HTLV-I infection |
6 |
3.8.E-03 |
| ko05200 |
Pathways in cancer |
5 |
1.9.E-02 |
| ko04514 |
Cell adhesion molecules (CAMs) |
4 |
9.3.E-03 |
| ko04650 |
Natural killer cell mediated cytotoxicity |
4 |
9.6.E-03 |
| ko05169 |
Epstein-Barr virus infection |
4 |
1.9.E-02 |
| ko04060 |
Cytokine-cytokine receptor interaction |
4 |
1.9.E-02 |
| ko04144 |
Endocytosis |
4 |
3.1.E-02 |
| ko05219 |
Bladder cancer |
3 |
9.0.E-03 |
| ko05144 |
Malaria |
3 |
9.0.E-03 |
| ko05323 |
Rheumatoid arthritis |
3 |
1.5.E-02 |
| ko04350 |
TGF-beta signaling pathway |
3 |
1.9.E-02 |
| ko05145 |
Toxoplasmosis |
3 |
2.7.E-02 |
| ko04310 |
Wnt signaling pathway |
3 |
3.9.E-02 |
| ko04670 |
Leukocyte transendothelial migration |
3 |
4.9.E-02 |
| ko05416 |
Viral myocarditis |
3 |
4.9.E-02 |
| ko05216 |
Thyroid cancer |
2 |
1.9.E-02 |
| ko05330 |
Allograft rejection |
2 |
2.7.E-02 |
| ko04672 |
Intestinal immune network for IgA production |
2 |
2.9.E-02 |
| ko04940 |
Type I diabetes mellitus |
2 |
3.0.E-02 |
| ko05332 |
Graft-versus-host disease |
2 |
3.5.E-02 |
| ko05320 |
Autoimmune thyroid disease |
2 |
3.5.E-02 |
| ko05210 |
Colorectal cancer |
2 |
4.0.E-02 |
|
Down-regulated target genes KEGG-Pathways
|
20
|
| ko05200 |
Pathways in cancer |
5 |
1.3.E-02 |
| ko04620 |
Toll-like receptor signaling pathway |
3 |
1.4.E-02 |
| ko04514 |
Cell adhesion molecules (CAMs) |
3 |
2.7.E-02 |
| ko05168 |
Herpes simplex infection |
3 |
3.7.E-02 |
| ko05210 |
Colorectal cancer |
2 |
3.7.E-02 |
| ko05213 |
Endometrial cancer |
2 |
3.7.E-02 |
| ko05218 |
Melanoma |
2 |
4.3.E-02 |
| ko05140 |
Leishmaniasis |
2 |
4.3.E-02 |
| ko05323 |
Rheumatoid arthritis |
2 |
4.3.E-02 |
| ko05133 |
Pertussis |
2 |
4.3.E-02 |
| ko05031 |
Amphetamine addiction |
2 |
4.3.E-02 |
| ko05142 |
Chagas disease (American trypanosomiasis) |
2 |
4.3.E-02 |
| ko04350 |
TGF-beta signaling pathway |
2 |
4.8.E-02 |
| ko04662 |
B cell receptor signaling pathway |
2 |
4.8.E-02 |
| ko05215 |
Prostate cancer |
2 |
4.8.E-02 |
